FanLin Kong: AAPS 2011 Profile - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FanLin Kong: AAPS 2011 Profile


FanLin Kong



FanLin Kong

FanLin Kong is enrolled in the PhD program of the University of Texas Graduate School of Biomedical Sciences. She also works as a graduate research assistant at the University of Texas M.D. Anderson Cancer Center. Her research interest is focused on radiopharmaceutical development in oncology. She will graduate by the end of this year and start her research career as an instructor at M.D. Anderson Cancer Center.

View Full Research Presentation

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca

Click here